Printer Friendly

Biodesix's GeneStrat Liquid Biopsy Testing Now Includes ROS1 and RET Mutations.

M2 PHARMA-February 3, 2017-Biodesix's GeneStrat Liquid Biopsy Testing Now Includes ROS1 and RET Mutations

(C)2017 M2 COMMUNICATIONS

- US-based molecular diagnostics company Biodesix, Inc's GeneStrat liquid biopsy for patients with cancer now includes ROS1 and RET in addition to EGFR sensitising; EGFR resistance (T790M), KRAS, BRAF mutations; and EML4-ALK fusions, the company said.

GeneStrat is a non-invasive blood test analysing circulating tumor DNA and RNA. The test provides fast, highly sensitive results in 72 hours for non-small cell lung cancer (NSCLC) patients.

Physicians can utilise GeneStrat as part of the Biodesix Lung Reflexmulti-omic, liquid biopsy testing strategy when reflexed to VeriStratproteomic testing, to identify more aggressive tumor growth and inform likely patient benefit from treatment.

In 2016, nearly 80% of physicians who ordered GeneStrat chose to reflex to VeriStrat testing.

The VeriStrat test and the genes tested in GeneStrat are covered by Medicare and many private payers.

Biodesix Lung Reflex testing offers significant advantages for patients and their physicians over tissue testing.

With results available within 72 hours, GeneStrat and VeriStrat deliver comprehensive information for physicians to support critical treatment decisions as early as initial diagnosis, and can expedite appropriate treatment for patients.

Tissue biopsy sample availability is often limited, and awaiting tumor biomarker results may delay treatment decisions and ultimately impact patient outcomes.

Blood testing can also capture mutation information regardless of tumor location or heterogeneity, while tissue testing may miss relevant molecular alterations.

Biodesix discovers, develops and commercialises multivariate protein and genomic liquid biopsy tests, including the GeneStrat and VeriStrat tests, that deliver results within 72 hours.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 3, 2017
Words:270
Previous Article:Imara Receives Orphan Drug Designation for Sickle Cell Disease Treatment.
Next Article:US FDA Approves Bristol-Myers Squibb's Opdivo in Previously Treated Urothelial Carcinoma.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters